Jasper Therapeutics Secures $132M In Financing; Advances Post-Kira Clinical Pipeline
Jasper Therapeutics (JSPR) reported Q2 2026 results and a corporate update after completing its all-stock acquisition of Kira Pharmaceuticals on July 16, 2026. The company raised about $132M via a private placement of non-voting convertible preferred stock. Cash was $7.3M at June 30. Net loss was $2.8M. Pipeline updates include KP-104, briquilimab, and KP-701.
How this was made
The 30-second read
Why it matters
The combination of a new $132M financing and a defined set of near-to-mid-term clinical and FDA touchpoints (interim Phase 2 data in Q4 2026, EOP2 for KP-104 in H1 2027, pre-BLA for briquilimab in Q1 2027, and CTA/IND for KP-701 in Q1 2027) provides actionable catalyst timing and runway clarity.
Market read
Traders can reassess dilution and runway risk after the $132M financing, then trade around the stated FDA and clinical timing windows.
What to watch
Cash is only $7.3M at June 30, so traders may focus on burn rate versus the true net proceeds and the probability of hitting the stated FDA/clinical milestones.
Background
Jasper is a clinical-stage biotech focused on immune-mediated diseases and just combined with Kira Pharmaceuticals via an all-stock acquisition completed July 16, 2026.
Ticker impact
Jasper reported Q2 results, completed its all-stock Kira acquisition, and raised about $132M to fund operations through 2H 2028.
Shares may see support from the $132M gross proceeds and improved runway, with upside sensitivity to the stated FDA meeting and trial interim data windows.
The article discloses a new capital raise and acquisition completion plus concrete planned regulatory and clinical timing (Q4 2026 interim data, H1 2027 EOP2, Q1 2027 pre-BLA/CTA-IND).
Market effects
Reinforces ongoing capital access for small-cap biotech and highlights continued focus on complement and anti-KIT immunology programs.
No clear regional spillover beyond US small-cap biotech sentiment.
Limited; primarily affects US-listed biotech risk appetite and clinical-stage funding conditions.
Counterpoint
The $132M gross proceeds may still imply meaningful dilution or preferred economics, which can cap upside despite improved runway.
Key entities
- companyJasper Therapeutics Inc.
Clinical-stage biotech; reported Q2 2026 results, completed Kira acquisition, and raised about $132M to fund operations through 2H 2028.
- companyKira Pharmaceuticals
Acquired by Jasper in an all-stock transaction completed July 16, 2026.
- investorAffinity Asset Advisors
Led the private placement of non-voting convertible preferred stock.
- investorIkarian Capital
Participated in leading the private placement of non-voting convertible preferred stock.
- drug_programKP-104 (vensobafusp alfa)
Complement inhibitor in Phase 2 basket trial; interim Stage 1 data expected in Q4 2026 and EOP2 meeting planned for PNH in H1 2027.
